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EVALUATION OF THE TOPICAL THERAPEUTIC EFFICACY OF HEXETIDINE
(STERISIL) IN VARIOUS DERMATOSES
A PRELIMINARY REPORT
ASHTON L. WELSH, M.D. AND MITCHELL EDE, M.D.
Our report represents an attempted evaluation
of the therapeutic efficacy of a new "syntho-
biotic," Hexetidine (Sterisil), a synthetic organic
compound with broad-spectrum antibacterial
and antifungal activity, when applied topically,
for the treatment of selected dermatoses.
Sterisil (Brand of Hexetidine), 5-amino-i,3 - bis - (3 - ethyihexyl) - 5 - methyl-
hexahydropyrimidine, represented by the struc-
tural formula shown following, has been reported
to possess bactericidal activity manifested by
interference with vital metabolic processes neces-
sary for the growth of pathogenic organisms (1).
Review of the experience of others with Hexet-
idine (Sterisil Vaginal Gel) reveals no evidence
that this agent is a primary irritant or sensitizer
(3, 4, 5, 6). Review of the experience in veterinary
practice reveals that Hexetidine has been found
efficacious for controlling and clearing pyogenic
infections of the skin of dogs (7). Review of the
preliminary dermatological studies in humans
indicates that Hexetidine (Sterisil) in ointment
and liquid forms might prove of value in the
treatment of dermatoses caused by, or compli-
cated by bacterial and mycotic infections (8).
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Fifty-four strains of gram-negative and gram-
positive organisms (including a number of freshly-
isolated infectious strains of staphylococci and
streptococci resistant to penicillin and other
antibiotics) have been found sensitive (2). Re-
sistance to Hexetidine, and cross-resistance
between antibiotics and Hexetidine did not
develop. Pathogenic fungi (including trichophy-
ton and microsporum, candida, cryptococcus,
blastomyces and histoplasma) have been
inhibited by therapeutic concentrations (2).
Hexetidine has been found to be trichomonacidal
in concentrations of 1:128,000.
This "synthobiotic" possesses an unusually
strong affinity for tissue, as demonstrated by
laboratory experiments when several hours of
continuous washing failed to remove, com-
pletely, Hexetidine from tissue structures.
Physiologic and pathologic secretions, therefore,
would not be likely to remove, easily, Hexetidine
from sites of topical application.
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MATERIALS AND METHOD
Hexetidine (Sterisil) was used by us in the
following forms:
Ointment*containing 0.1% Hexetidine in
synthetic gum base
Liquid*__containing 0.5% Hexetidine in fat-
soluble solvent
Vaginal Gel—containing 0.1% Hexetidine in
tragacanth base
All patients (from private practice) were in-
structed to apply the ointment and/or liquid,
first, to a small area, watch for and report any
untoward reaction (such as increased irrita-
tion, erythema, extension of an eruption, and the
like) before application was made to large areas.
If untoward reaction should occur, patients were
instructed to stop use immediately, and return
for observation. Applications of ointment and/or
liquid were prescribed from one to four times
* Hexetidine Ointment and Liquid used in this
study were generously supplied by Warner-
Chilcott Laboratories, Morris Plains, New Jersey.
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TABLE I
Duration of Therapy in
Months Response to Therapy
Number —
Disease Entities of
Patients Less
than 1 1—3
100%
Clear
75/
99%Im-
proved
30%—
Im
proved
No im-
prove-
ment
Sus-
pectedbut u's-
confirmed
reaction
Bacterial Etiology
Eczematous Eruptions (including 27 9 14 4 13 9 3 2
Atopic Dermatitis and Chronic In-
fectious Eczematoid Dermatitis)
Erythema Perstans 1 1 1
Folliculitis (Nonspecific) 7 5 2 5 2
Impetigo (Streptococcic and/or 9 7 2 6 2 1
Staphylococcic)
Intertrigo 7 6 1 3 4
Paronychia 5 5 2 3
Pyogenic Infections (Miscellaneous) 5 4 1 3 2
Mycotic Etiology
Erosio Interdigitalis Blastomycetica 1 1 1
Monilia 5 1 3 1 2 3
Tinea Capitis 8 8 8
Tinea Corporis 3 3 3
TineaCruris 3 2 1 2 1
TineaManuum 2 1 1 1 1
Tinea Pedis 34 20 10 4 22 12
Tinea Unguium 20 6 14 13 7
Tinea Versicolor 6 3 3 4 2
Unknown Etiology
TOTAL
11
154
5
72
6
58
7
24 71
4
65 15 1 2
daily (usually twice daily), depending upon the
condition. Vaginal Gel was prescribed one appli-
cator-full every other night for a total of six
applications, treatment being continued through
one menstrual period. Patients were observed at
weekly intervals. This report is based on a study-
period of six months.
RESULTS
The Table I indicates disease entities, number
of patients, duration of therapy, and response.
COMMENT
Disease entities of bacterial origin
Two patients experienced severe and prolonged
"burning" following application of the liquid
form of Hexetidine, and therapy with that agent
was discontinued. Inasmuch as both patients
were able to derive beneficial effect, a month
later, from usc of Hexetidinc in ointment form,
we have classified those two patients as having
"suspected but unconfirmed" reactions to the
liquid vehicle, rather than to Hcxetidinc,
Twelve patients, with dermatoses complicated
by infectious organisms known to be resistant to
antibiotic therapy, responded favorably to
therapy with Hexetidine. There was no mani-
festation of incompatibility between Hcxetidine
and concomitant topical use, where indicated, of
the following antibiotics, singly or in combina-
tion: bacitracin, erythromycin, gramicidin, neo-
mycin, oxytetracyclinc, polymyxin and tetra-
cycline.
For dermatological conditions in which anti-
inflammatory therapy was indicated, hydrocorti-
sone (and/or the 9-alpha fluoro derivative, pred-
nisone,prcdnisolone) topical agents, in appropriate
concentrations, were prescribed for applica-
tion concomitantly with Hexetidinc. No in-
compatibility between Hcxctidine and the
steroids was manifested. As with other anti-
cczcmatous medicaments (9, 10) there appeared
to be exerted some synergistic action between
hydrocortisone and Hexetidine.
Five patients with vulvar and pcrianal
eczcmatization resulting from non-specific vagi-
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nitis, were asymptomatie in less than eight weeks
following therapy with Hexetidine topically, in
ointment form, and intravaginally, in gel form.
Disease entities of mycotic origin
Activity of Hexetidine against the yeastlike
organism responsible for the interdigital inter-
trigo (erosio interdigitalis blastomycetica), in
one patient, was not demonstrated by clinical
improvement. There may have been, however,
some inhibitive action exerted by Hexctidinc
against multiplication of the fungus, inasmuch as
the patient's condition seemed to be kept in
abeyance, rather than improved.
Only slight improvement of the objective
symptoms of five patients with cutaneous lesions
due to Monilia albicans (diagnosis confirmed by
culture) on Hexetidine therapy was observed,
although marked improvement of subjective
symptoms, such as pruritus, burning, smarting
and tingling, was reported by the patients them-
selves. When concomitant topical application of
nystatin with Hexetidine was prescribed for
these patients, improvement, objectively, was
more pronounced. There was no manifestation of
incompatibility between Hexctidine and nystatin.
Lesions of eight patients with tinca capitis
(infection in six patients being caused by Micro-
sporum audouini, and in two patients, by Micro-
sporum canis) demonstrated marked improve-
ment following use of Hexetidinc for only one
month. At the end of three months, all of these
patients were almost entirely free of infection by
fungi. Further observation of these eight patients,
as well as observation of a much larger number of
patients, will be necessary in order to make ade-
quate appraisal of the therapeutic efficacy of
Hexetidine in tinea capitis. Response of patients
with tinea corporis, cruris, manuum, pedis and
versicolor (diagnoses confirmed by microscopic
examination, or culture, or both) indicated that
Hexeditinc is effective against mycotic infections
caused by trichophyton and microsporum. Of
34 patients with tinea pedis, 17 had received and
were receiving, at the time this study was under-
taken, therapy with other antifungal mcdica-
mcnts, such as undecylenic acid, the caprylates
and salicylanilide. The fact that trichophyton and
microsporum develop resistance to these ther-
apeutic measures was demonstrated when these
17 patients were subsequently treated with
Hexetidine, the response to which was favorable
and prompt. Only one of the 17 patients had
recurrence, when medication was withdrawn.
Resumption of Hexetidine was again effective.
Hexetidine proved to be an efficacious ther-
apeutic agent for lesions involving the oral, rectal
and vaginal mucosa. We observed no signs of
irritation or sensitization, and no evidence of
fungal (or bacterial) resistance following pro-
longed usc.
Disease entities of unknown etiology
It is likewise too soon for adequate appraisal
of the activity of Hcxetidinc on Pityrosporum
ovale, but six patients with seborrhea capitis
have cleared promptly, and have remained clear,
with continued use of this agent.
CONCLUSIONS
We report preliminary clinical observations on
Hcxetidine (Stcrisil), when used for the treatment
of 154 patients with selected dermatoses. Favor-
able response to therapy indicates that Hexet-
idine is a broad-spectrum antibacterial and anti-
fungal agent.
Our observations seem to indicate, further,
that Hexetidine not only is antibacterial and anti-
fungal (in the sense that it prevents growth), but,
also, that it is germicidal and fungicidal (in the
sense that it destroys microorganisms and fungi).
Further studies will be required to establish
extent of the therapeutic activity of this "syntho-
biotic".
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